RE: Turner Pope update2 Oct 2024 17:53
Okehurst, TP note:
c.£32.5m cash-in-hand at end-June 2024 stage, together with expected net proceeds from disposal of the Diagnostics division (for which credible indicative offers have already started to be received with further bids anticipated), should provide sufficient runway to complete AVA6000’s Ph.2 study along with development of pre|CISION™’s next generation programmes
Plenty cash for current plans. As you’ve said, pay in cash if you’re confident, pay in shares if you’re prudent.